Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong financial backing and strategic plans for NDV-01 and sepranolone, but with notable risks in supply chain and financial management. The Q&A section highlights uncertainties, particularly regarding compliance with FDA requirements and market adoption challenges. Despite a positive cash position and reduced R&D expenses, the increase in net loss and operational costs raises concerns. The lack of clear guidance on FDA expectations and market strategy tempers enthusiasm, leading to a neutral stock price prediction.
Key Financial Performance
Cash Balance Relmada closed 2025 with a cash balance of $93 million, which includes net proceeds of approximately $94 million from an underwritten stock offering announced on November 5, 2025. This compares to cash, cash equivalents, and short-term investments of approximately $45 million at December 31, 2024. The increase is due to the stock offering and a $160 million private financing announced on March 9, 2025, with net proceeds of approximately $150 million.
Research and Development Expense For Q4 2025, R&D expense totaled $8.1 million compared to $11 million in Q4 2024, a decrease of $2.9 million. The decrease was primarily driven by a reduction in study costs associated with the completion of two Phase III trials for REL-1017, partially offset by increased costs related to the start-up of the Phase III NDV-01 trials and Phase IIb sepranolone study, as well as additional R&D personnel.
General and Administrative Expense For Q4 2025, G&A expense totaled $12.3 million compared to $8.1 million in Q4 2024, an increase of $4.2 million. The increase was primarily driven by higher compensation costs, partially offset by a decrease in stock compensation costs.
Net Cash Used in Operating Activities For Q4 2025, net cash used in operating activities was $14.6 million compared to $8.8 million in Q4 2024, reflecting an increase of $5.8 million. The increase was due to higher operational expenses.
Net Loss For Q4 2025, the net loss was $19.9 million or $0.27 per basic and diluted share compared to a net loss of $18.7 million or $0.62 per basic and diluted share in Q4 2024. The increase in net loss was driven by higher operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NDV-01: NDV-01 is a sustained release formulation of gemcitabine and docetaxel for treating non-muscle invasive bladder cancer (NMIBC). Phase II study showed compelling 12-month efficacy data with a 76% complete response rate and favorable safety profile. Phase III RESCUE program to start mid-2026 with two pathways: adjuvant therapy for intermediate risk bladder cancer (75,000 patients in the U.S.) and second-line treatment for BCG-unresponsive patients (5,000 patients in the U.S.).
Sepranolone: Sepranolone has demonstrated proof of concept in Tourette syndrome and is being prepared for a proof-of-concept study in Prader-Willi syndrome, starting mid-2026.
Financial Strength: Completed $160 million private financing, providing capital through 2029, including completion of NDV-01 Phase III program.
Team Expansion: Strengthened development team with the appointment of Dr. Raj Pruthi as Chief Medical Officer, Oncology, and established a Scientific Advisory Board.
Regulatory Strategy for NDV-01: Aligned with FDA for two registrational pathways for NDV-01, targeting adjuvant therapy and second-line treatment for NMIBC.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company’s forward-looking statements are subject to risks and uncertainties, as highlighted in their cautionary statements and SEC filings. This includes potential challenges in obtaining FDA approval for their NDV-01 program and other regulatory hurdles.
Clinical Trial Risks: The success of the NDV-01 program and sepranolone depends on the outcomes of ongoing and future clinical trials. Any unfavorable results or delays in these trials could adversely impact the company’s strategic objectives.
Market Adoption Risks: Despite promising data, there is no guarantee that NDV-01 will achieve widespread adoption among urologists and patients, especially given the competitive landscape and the need to establish it as a best-in-class therapy.
Financial Risks: Although the company has secured funding through 2029, the high costs associated with clinical trials and operational expenses could pose financial challenges if unexpected costs arise or if additional funding is required.
Supply Chain Risks: The company is in the process of establishing a supply chain for sepranolone. Any disruptions or delays in this process could impact the initiation and progress of the proof-of-concept study for Prader-Willi syndrome.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NDV-01 Phase III RESCUE Program: Relmada plans to initiate the Phase III RESCUE program for NDV-01 in mid-2026. The program includes two independent registrational pathways: Pathway 1 focuses on adjuvant therapy following TURBT in intermediate-risk bladder cancer patients (approximately 75,000 patients annually in the U.S.), and Pathway 2 targets second-line treatment for BCG-unresponsive patients (approximately 5,000 patients annually in the U.S.). Initial 3-month response data from Pathway 2 is expected by the end of 2026.
Sepranolone Proof-of-Concept Study: A proof-of-concept study for sepranolone in Prader-Willi syndrome is planned to begin in mid-2026. Preparations include engaging with the FDA on trial design and establishing a supply chain.
Financial Guidance: Relmada has secured sufficient funding to support operations through 2029, including the completion of the NDV-01 Phase III RESCUE program.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Will you present additional data from your Phase II study, and can we expect updates every 3 months? Will there be data at AUA?
A:Updated 12-month data will be presented at AUA, and data will be shared externally every 3 months as the trial progresses.
Q:How are you ensuring that second-line patients are truly second-line and not third-line?
A:The study limits prior therapy lines to two. The team will also evaluate 15 patients at 3 months to ensure compliance with this criterion.
Q:Will the 3-month data from your Phase III BCG unresponsive second-line and responsive patients include the entire patient population or just a portion?
A:The 3-month data will be from a portion of the patient population as it is an interim analysis.
Q:What is your expectation for enrollment cadence across your two studies, and can the drug's in-office profile serve as a recruitment advantage?
A:Enrollment is expected to proceed rapidly, especially for intermediate-risk patients, due to the drug's unique second-line therapy profile and in-office administration advantage.
Q:Has the FDA stipulated a minimum duration of follow-up required for all patients by submitting the NDA?
A:The FDA has not required a minimum follow-up duration but wants to see the totality of the data, including response and durability.
Q:What are you expecting to see in terms of the CR rate at the 3-month mark for Phase II and Phase III rescue?
A:The target for intermediate risk is a 2-year RFS of 75%. For BCG response in second-line, the CR rate should align with or exceed historical benchmarks like Valrubicin (8%) and KEYTRUDA (19%).
Q:How should we compare the patient baseline characteristics and CIS versus papillary split data to competitors?
A:Gem/Doce shows similar efficacy in CIS and papillary patients, with 12-month CR rates of 60%-61% in literature and 80%-84% in their data, which compares favorably to competitors.
Q:How much do you think the intermediate risk market might need to be built out by early launches?
A:The intermediate risk market is currently underdeveloped, with only 35% of patients receiving adjuvant therapy. This number is expected to grow as more data and approved agents become available.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the FDA's specific requirements for durability of response, using vague language like 'totality of the data' without specifying a clear benchmark.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CR
Doce
II study
III RESCUE
NDV class
NDV line
NDV practice
Pathway
Phase II
Phase III
RESCUE program
cancer therapy
completion Phase
cystectomy
efficacy Phase
evaluation NDV
expense month
financing
label trial
level
life
month NDV
month response
patient setting
physician
profile NDV
program NDV
program middle
program month
progression survival
rate month
risk NMIBC
risk bladder
safety profile
setting patient
strength
study Prader
summary Phase
therapy TURBT
RLMD Transcript
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call summary highlights a lack of revenue and increasing net losses, which are negative indicators. The company's operational updates and return plans were not discussed, adding uncertainty. The forward-looking statements emphasize potential risks, and the Q&A section offered no additional clarity. Although the company has sufficient funding until 2029, the increase in R&D and G&A expenses without revenue generation contributes to a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents a mixed picture: strong financial backing and strategic plans for NDV-01 and sepranolone, but with notable risks in supply chain and financial management. The Q&A section highlights uncertainties, particularly regarding compliance with FDA requirements and market adoption challenges. Despite a positive cash position and reduced R&D expenses, the increase in net loss and operational costs raises concerns. The lack of clear guidance on FDA expectations and market strategy tempers enthusiasm, leading to a neutral stock price prediction.
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
RLMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
